Open AccessAssociation Between Bone Mineral Density and Chronic Kidney Disease: Recent Perspective
Author(s) -
Lavanya Neerudi,
Keerthana Atla,
Gayathri Konduri,
Sireesha Vankodoth
Publication year - 2022
Publication title -
international journal of pharmaceutical sciences review and research
Language(s) - English
Resource type - Journals
ISSN - 0976-044X
DOI - 10.47583/ijpsrr.2022.v73i01.021
Subject(s) - hyperphosphatemia , fibroblast growth factor 23 , kidney disease , renal osteodystrophy , calcitriol , medicine , parathyroid hormone , vitamin d and neurology , endocrinology , bone remodeling , klotho , chronic kidney disease mineral and bone disorder , population , bone mineral , kidney , calcium , osteoporosis , environmental health
Mineral metabolism and bone health are both dependent on the kidney. It is not only the major site of vitamin D activation, but it is also the target organ for different regulatory hormones such as parathormone (PTH) and fibroblast growth factor-23 (FGF-23). Chronic kidney disease (CKD) is a global health issue that affects 5–10% of the global population. Vascular dedifferentiation/calcification, osteodystrophy, loss of klotho, and high FGF23 production are all symptoms of CKD-MBD, and research into its cause is continuing. The key parameters used in standard CKD-MBD diagnosis are biochemical (calcium, phosphorus, parathyroid hormone, alkaline phosphate) radiographic (X ray, MRI scan, CT, DEXA) and bone biopsy with subsequent pathological examination. Screening for calcium, phosphorus, alkaline phosphatase (ALP), and PTH, according to KDIGO criteria, is strongly recommended. The hallmarks of CKD-MBD treatment are the correction of hyperphosphatemia, hypocalcemia, and maintaining a sufficient calcitriol concentration.